Trial Profile
A Double-Blind, Randomized, Placebo-Controlled Trial To Evaluate The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- 20 Aug 2023 Status changed to discontinued.
- 08 Dec 2022 Status changed from recruiting to completed.
- 11 Dec 2019 Planned End Date changed from 1 Sep 2019 to 1 Sep 2021.